Saturday 17 October 2026
Export GANX’s income statement to Excel — free account
Gain Therapeutics, Inc.
GANX Healthcare Biotechnology
Gain Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $55,200.00, down 60.6% from fiscal 2022. In the quarter to June 2026, EPS grew 42.1%, free cash flow grew 8.22% and total debt fell 23.9%, each against the same quarter a year earlier.
1.26
0.07
−5.26%
Follow GANX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
2.11 | 6.22 | 4.26 | 3.81 | |
Current Ratio |
2.52 | 6.63 | 4.69 | 4.36 | |
Net Debt/EBITDA |
1.76 | 4.61 | 3.03 | 2.74 | |
Debt/Assets |
3.87% | 1.76% | 1.99% | 2.23% | |
Debt/Equity |
0.07 | 0.02 | 0.03 | 0.03 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.93 | 1.02 | 0.84 | 1.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.14) | (0.14) | (0.11) | (0.11) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.14) | (0.14) | (0.11) | (0.11) | |
Cash per Share |
0.25 | 0.63 | 0.39 | 0.31 | |
Shareholders Equity per Share |
0.17 | 0.56 | 0.33 | 0.26 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.17 | 0.56 | 0.33 | 0.26 | |
Free Cash Flow |
(4.93) | (4.62) | (4.73) | (4.68) | |
Working Capital |
6.35 | 18.88 | 14.34 | 11.54 | |
Net Current Asset Value |
5.46 | 17.98 | 13.49 | 10.84 | |
| Other line items | |||||
Average Payables |
1.34 | 0.89 | 1.83 | 1.97 | |
Average Assets |
12.67 | 17.47 | 15.18 | 12.63 | |
Average Common Equity |
7.41 | 12.95 | 9.89 | 7.49 |
Columns are period end dates